<DOC>
	<DOCNO>NCT01362764</DOCNO>
	<brief_summary>The purpose study compare single-dose pharmacokinetics ( drug absorb body , distribute within body , remove body ) solution formulation tablet formulation ; therefore low dose available tablet formulation ( 250 mg ) select .</brief_summary>
	<brief_title>A Study Assess Relative Bioavailability Two Abiraterone Acetate Suspension Formulations Compared Abiraterone Acetate Tablet Formulation Healthy Adult Volunteers</brief_title>
	<detailed_description>This open-label ( volunteer study staff know identity assign treatment ) study two abiraterone acetate suspension formulation , compare abiraterone acetate tablet formulation healthy volunteer . Approximately 30 healthy volunteer participate study . Each volunteer randomly assign 1 6 possible treatment sequence . The study consist screen phase ( within 21 day first study drug administration first period ) ; open-label treatment phase consist 3 single dose treatment period ; end-of-study withdrawal assessment do upon completion 72-hour ( Day 4 Period 3 , upon withdrawal ) sample evaluate drug absorb body , distribute within body , remove body time . A 7- 14-day washout period separate study drug administration . The duration participation study individual healthy volunteer 41 day maximum 55 day ( include screen ) . Safety monitor . Volunteers receive 250 mg dose abiraterone acetate tablet , suspension Formulation 1 , suspension Formulation 2 accord treatment sequence . Abiraterone acetate tablet must swallow whole chewed , divide , dissolve crush take 240 mL noncarbonated water . For suspension , volunteer drink content vial . The vial rinse 10 mL water , volunteer ask drink rinse water .</detailed_description>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Having sign informed consent document Agreeing use adequate contraception method , deem appropriate investigator ( e.g. , vasectomy , doublebarrier , partner use effective contraception ) donate sperm study 3 month receive last dose study drug Body mass index ( weight [ kg ] /height2 [ ] 2 ) 18 30 kg/m2 ( inclusive ) , body weight less 50 kg Blood pressure ( volunteer sit 5 minute ) 90 140 mm Hg systolic , inclusive , high 90 mm Hg diastolic screening Days 21 Day 1 Having 12lead electrocardiogram ( ECG ) consistent normal cardiac conduction function Morphology consistent healthy cardiac conduction function History current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder ( include abnormal bleeding blood dyscrasia ) , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , renal hepatic insufficiency , thyroid disease , neurologic psychiatric disease , infection , illness investigator considers exclude volunteer could interfere interpretation study result Clinically significant abnormal value hematology , clinical chemistry urinalysis screen admission study center deem appropriate investigator Clinically significant abnormal physical examination , vital sign 12lead ECG screen admission study center deem appropriate investigator Use prescription nonprescription medication ( include vitamin herbal supplement ) , except acetaminophen , within 14 day first dose study drug schedule History , reason believe volunteer history drug alcohol abuse within past 2 year</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Abiraterone Acetate</keyword>
	<keyword>ZYTIGA</keyword>
</DOC>